Back to Search
Start Over
Merck enters into exclusive global license with LaNova Medicines to develop, manufacture & commercialize LM-299, an investigational anti-PD-1/VEGF bispecific antibody
- Source :
- PharmaBiz. November 16, 2024
- Publication Year :
- 2024
-
Abstract
- Merck, known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.816471555